STAMFORD, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical
company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively
targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on
Thursday, March 15, 2018, at 4:30 p.m. ET to report fourth quarter and full year 2017 financial results and provide a corporate
update.
To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and
refer to conference ID 2689187. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors
section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the
call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new
chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors (KORs). Cara
is developing a novel and proprietary class of product candidates, led by CR845/difelikefalin, a first-in-class KOR agonist that
targets the body's peripheral nervous system, as well as certain immune cells. In Phase 2 trials, KORSUVATM
(CR845/difelikefalin) injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement
in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP)
and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Additionally, CR845/difelikefalin has
demonstrated efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically
associated with currently available opioid pain therapeutics.
The United Stated Food and Drug Administration (FDA) has conditionally accepted KORSUVA™ as the trade name for
difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully
evaluated by any regulatory authority.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations
212-362-1200
michael@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
